EU-AIMS general approach and strategy
Our overall strategy reflects our belief that neither top-down clinical and translational studies, nor bottom-up model system analysis can impact on ASD alone. Rather, we need to integrate proven technologies around (for example) animal models and PET, together with new approaches (e.g. functional MRI (fMRI), induced pluripotent stem cells (iPSCs) and multi-omics). To achieve this we plan 5 major deliverables (figure, below) which strike a pragmatic balance between advances that are more certain in the next 3-5 years (enhanced and enriched animal models, new imaging techniques, advanced analyses) and lines of research that may carry more risk but will be transformative over a longer timeframe (genetics, transcriptomics and proteomics for patient stratification and response prediction).
To facilitate the organisation and management, EU-AIMS is structured in 6 workpackages (WPs), which together comprise the project. Each WP has an academic and an EFPIA lead who is responsible for the management and the results of their WP.
The figure below shows the structure of the different WPs and their interdependencies.
By clicking on the different WPs you can find out more about their tasks and objectives